Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 31;2013(5):CD000951.
doi: 10.1002/14651858.CD000951.pub2.

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis

Beverley Shea  1 , Michael V Swinden, Elizabeth Tanjong Ghogomu, Zulma Ortiz, Wanruchada Katchamart, Tamara Rader, Claire Bombardier, George A Wells, Peter Tugwell
Affiliations

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis

Beverley Shea et al. Cochrane Database Syst Rev. .

Abstract

Background: Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic or folinic acid during treatment with MTX may ameliorate these side effects.

Objectives: To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.

Search methods: We originally performed MEDLINE searches, from January 1966 to June 1999. During the update of this review, we searched additional databases and used a sensitive search strategy designed to retrieve all trials on folic acid or folinic acid for rheumatoid arthritis from 1999 up to 2 March 2012.

Selection criteria: We selected all double-blind, randomised, placebo-controlled clinical trials (RCTs) in which adult patients with rheumatoid arthritis were treated with MTX (at a dose equal to or less than 25 mg/week) concurrently with folate supplementation. In this update of the review we only included trials using 'low dose' folic or folinic acid (a starting dose of ≤ 7 mg weekly).

Data collection and analysis: Data were extracted from the trials, and the trials were independently assessed for risk of bias using a predetermined set of criteria.

Main results: Six trials with 624 patients were eligible for inclusion. Most studies had low or unclear risk of bias for key domains. The quality of the evidence was rated as 'moderate' for each outcome as assessed by GRADE, with the exception of haematologic side effects which were rated as 'low'. There was no significant heterogeneity between trials, including where folic acid and folinic acid studies were pooled.For patients supplemented with any form of exogenous folate (either folic or folinic acid) whilst on MTX therapy for rheumatoid arthritis, a 26% relative (9% absolute) risk reduction was seen for the incidence of GI side effects such as nausea, vomiting or abdominal pain (RR 0.74, 95% CI 0.59 to 0.92; P = 0.008). Folic and folinic acid also appear to be protective against abnormal serum transaminase elevation caused by MTX, with a 76.9% relative (16% absolute) risk reduction (RR 0.23, 95% CI 0.15 to 0.34; P < 0.00001), as well as reducing patient withdrawal from MTX for any reason (60.8% relative (15.2% absolute) risk reduction, RR 0.39, 95% CI 0.28 to 0.53; P < 0.00001).We analysed the effect of folic or folinic acid on the incidence of stomatitis / mouth sores, and whilst showing a trend towards reduction in risk, the results were not statistically significant (RR 0.72, 95% CI 0.49 to 1.06)It was not possible to draw meaningful conclusions on the effect of folic or folinic acid on haematologic side effects of methotrexate due to small numbers of events and poor reporting of this outcome in included trials.It does not appear that supplementation with either folic or folinic acid has a statistically significant effect on the efficacy of MTX in treating RA (as measured by RA disease activity parameters such as tender and swollen joint counts, or physician's global assessment scores).

Authors' conclusions: The results support a protective effect of supplementation with either folic or folinic acid for patients with rheumatoid arthritis during treatment with MTX.There was a significant reduction shown in the incidence of GI side effects, hepatic dysfunction (asmeasured by elevated serum transaminase levels) as well as a significant reduction in discontinuation of MTX treatment for any reason. A trend towards a reduction in stomatitis was demonstrated however this did not reach statistical significance.This updated review with its focus on lower doses of folic acid and folinic acid and updated assessment of risk of bias aimed to give a more precise and more clinically relevant estimate of the benefit of folate supplementation for patients with rheumatoid arthritis receiving methotrexate.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Study flow diagram.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
3
3
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
1.1
1.1. Analysis
Comparison 1 Folic acid versus placebo, Outcome 1 Nausea / GI upset.
1.2
1.2. Analysis
Comparison 1 Folic acid versus placebo, Outcome 2 Stomatitis.
1.3
1.3. Analysis
Comparison 1 Folic acid versus placebo, Outcome 3 Liver toxicity.
1.4
1.4. Analysis
Comparison 1 Folic acid versus placebo, Outcome 4 Neutropenia.
1.5
1.5. Analysis
Comparison 1 Folic acid versus placebo, Outcome 5 Total withdrawals.
1.6
1.6. Analysis
Comparison 1 Folic acid versus placebo, Outcome 6 Tender Joints.
1.7
1.7. Analysis
Comparison 1 Folic acid versus placebo, Outcome 7 Swollen Joints.
1.8
1.8. Analysis
Comparison 1 Folic acid versus placebo, Outcome 8 Patient global assessment.
2.1
2.1. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 1 Nausea / GI upset.
2.2
2.2. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 2 Stomatitis.
2.3
2.3. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 3 Liver toxicity.
2.4
2.4. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 4 Neutropenia.
2.5
2.5. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 5 Total withdrawals.
2.6
2.6. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 6 Tender Joints.
2.7
2.7. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 7 Swollen Joints.
2.8
2.8. Analysis
Comparison 2 Folinic acid versus placebo, Outcome 8 Patient global assessment.
3.1
3.1. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 1 Nausea / GI upset.
3.2
3.2. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 2 Stomatitis.
3.3
3.3. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 3 Liver toxicity.
3.4
3.4. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 4 Neutropenia.
3.5
3.5. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 5 Total withdrawals.
3.6
3.6. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 6 Tender Joints.
3.7
3.7. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 7 Swollen Joints.
3.8
3.8. Analysis
Comparison 3 Folic or folinic acid versus placebo, Outcome 8 Patient Global Assessment.
4.1
4.1. Analysis
Comparison 4 Folic acid versus folinic acid, Outcome 1 GI side effects.
4.2
4.2. Analysis
Comparison 4 Folic acid versus folinic acid, Outcome 2 Liver toxicity.
4.3
4.3. Analysis
Comparison 4 Folic acid versus folinic acid, Outcome 3 Total withdrawals.
See this image and copyright information in PMC

Update of

Comment in

References

References to studies included in this review

Buckley 1990 {published data only}
    1. Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. Journal of Rheumatology 1990;17:1158‐61. - PubMed
Morgan 1990 {published data only}
    1. Morgan SL, Baggott J, Vaughn W, Young P, Austin J, Krumdieck C, Alarcon S. The effect of folic acid supplementation on the toxicity of low‐dose methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 1990;33(1):9‐18. - PubMed
Morgan 1994 {published data only}
    1. Morgan S, Baggot J, Vaughn W, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double‐blind, placebo controlled trial. Annals of Internal Medicine 1994;121(11):833‐41. - PubMed
Shiroky 1993 {published data only}
    1. Shiroky J, Neville C, Esdaile J, et al. Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomized, double‐blind, placebo controlled trial. Arthritis and Rheumatism 1993;36(3):795‐803. - PubMed
Van Ede 2001 {published data only}
    1. Ede A, Laan R, Blom H, Huizinga T, Haagsma C, Giesendorf B, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene. A genetic risk factor for methotrexate‐related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism 2001;44(11):2525‐30. - PubMed
Weinblatt 1993 {published data only}
    1. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 weeks randomized placebo controlled trial. Journal of Rheumatology 1993;20:950‐2. - PubMed

References to studies excluded from this review

Andersen 1997 {published data only}
    1. Andersen LS, Hansen EL, Knusdsen JB, Wester JU, Hansen GVO, Hansen TM. Propectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: Relation to withdrawal and side effects. Journal of Rheumatology 1997;24(5):830‐7. - PubMed
Canadian Group 1992 {unpublished data only}
    1. The Canadian Leucovorin Study Group. Low dose methotrexate with leucovorin in the management of rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 1993;36(6):795‐803. - PubMed
Griffith 2000 {published data only}
    1. Griffith S, Fisher J, Clarke S, Montgomery B, Jones P, Saklatvala J, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?. Rheumatology 2000;39:1102‐9. - PubMed
Hanrahan 1988 {published data only}
    1. Hanrahan P, Russell A. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. Journal of Rheumatology 1988;15:1078‐80. - PubMed
Joyce 1991 {published data only}
    1. Joyce D, Will D, Hoffman D, Laing B, Blackbourn S. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Annals of the Rheumatic Diseases 1991;50:913‐4. - PMC - PubMed
Morgan 1998 {published data only}
    1. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention. Journal of Rheumatology 1998;25:441‐6. - PubMed
Stewart 1991 {published data only}
    1. Stewart K, Mackenzie A, Clough J, Wilke W. Folate supplementation in methotrexate‐treated rheumatoid arthritis patients. Seminars in Arthritis and Rheumatism 1991;20(5):332‐8. - PubMed
Tishler 1988 {published data only}
    1. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis and Rheumatism 1988;31(7):906‐8. - PubMed
Weinblatt 1992 {published data only}
    1. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin plus methotrexate (MTX) in rheumatoid arthritis (RA): an eight week placebo controlled randomized trial [Abstract]. Arthritis and Rheumatism 1992;Suppl:S340.

Additional references

Anderson 1985
    1. Andersen P, West S, O'Dell J, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine 1985;103:489‐96. - PubMed
Arnett 1988
    1. Arnett F, Edworthy S, Bloch D, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315‐24. - PubMed
Brooks 1995
    1. Brooks P, Day R. Toxicity of antirheumatic drugs. Journal of Rheumatology 1995;22(5):998‐90. - PubMed
Chakravarty 2008
    1. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al. BSR/BHPR guideline for disease‐modifying anti‐rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008;47(6):924‐5. [PUBMED: 16940305] - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). The Cochrane Collaboration, 2011. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT,Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286‐91. - PMC - PubMed
Dijkmans 1995
    1. Dijkmans B. Folate supplementation and methotrexate. British Journal of Rheumatology 1995;34:1172‐4. - PubMed
Drummond 1995
    1. Drummond M, Bosi Ferraz M, Mason J. Assessing the cost effectiveness of NSAID: an international perspective. Journal of Rheumatology 1995;22(7):1408‐14. - PubMed
Dutch Society of Rheumatology 2011
    1. Dutch Society of Rheumatology. Guidelines for Medication: Methotrexate [Nederlandse Vereniging voor Reumatologie. Richtlijnen Medicijnen: Methotrexaat]. Available via http://www.nvr.nl/richtlijnen/Totstandkoming_richtlijnen September 2009 (Updated 2011).
Felson 1990
    1. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis. Results of two meta‐analyses. Arthritis and Rheumatism 1990;33(10):1449‐61. - PubMed
Felson 1992
    1. Felson D, Anderson J, Meenan R. Use of short‐term efficacy/toxicity tradeoffs to select second‐line drugs in rheumatoid arthritis: A meta‐analysis of published clinical trials. Arthritis and Rheumatism 1992;35:1117‐25. - PubMed
Furst 1994
    1. Furst D, Clements P. Pharmacological approaches. SAARDs‐ II. Rheumatology 1994;13:1‐8.
GUIPCAR group 2007
    1. GUIPCAR Group. Clinical practice guideline for the management of rheumatoid arthritis in Spain. Spanish Society of Rheumatology, Madrid 2007:301.
Hartman 2004
    1. Hartman M, VanEde AE, Severens JL, Laan R, Putte L, Wilt G. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. Journal Of Rheumatology 2004;31(5):902‐8. - PubMed
Hedges 1982
    1. Hedges LV. Estimation of effect size from a series of independent experiments. Psychological Bulletin 1982;92:490‐499.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jackson 1984
    1. Jackson R. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacology & Therapeutics 1984;25:61‐82. - PubMed
Katchamart 2010
    1. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010;4:pp CD008495. - PMC - PubMed
Kremer 1986
    1. Kremer J, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis and Rheumatism 1986;29:832‐4. - PubMed
Kremer 1995
    1. Kremer J. The changing face of therapy for rheumatoid arthritis. Rheumatic Diseases Clinics of North America 1995;21(3):845‐52. - PubMed
Leeb 1995
    1. Leeb BF, Witzmann G, Ogris E, Studnicka‐Benke A, Andel I, Schweitzer H, Smolen JS. Folic acid and cyanocobalamin levels in serum and erythrocytes during low‐dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clinical and Experimental Rheumatology 1995 Jul‐Aug;13(4):459‐63. - PubMed
Majithia V 2007
    1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. American Journal of Medicine 2007;120 (11):36–9. - PubMed
Maxwell 2009
    1. Maxwell L, Singh J. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009;4:pp CD007277. - PMC - PubMed
Morgan 1987
    1. Morgan S, Baggot J, Altz‐Smith M. Folate status of rheumatoid arthritis patients receiving long‐term, low‐dose methotrexate therapy. Arthritis and Rheumatism 1987;30:1348‐56. - PubMed
Morgan 1991
    1. Morgan S, Baggot J, Refsum H, Ueland P. Homocysteine levels in patients with rheumatoid arthritis treated with low‐dose methotrexate. Clinical Pharmacology and Therapeutics 1991;50:547‐56. - PubMed
Morgan 1993
    1. Morgan S, Alarcón G, Krumdieck C. Folic acid supplementation during methotrexate therapy: it makes sense [Editorial]. Journal of Rheumatology 1993;20(6):929‐30. - PubMed
Navarro Sarabia 2005
    1. Navarro Sabia F, Ariza Ariza R, Hernandez Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2] - DOI - PMC - PubMed
Petitti 1994
    1. Petitti D. Meta‐analysis, decision analysis, and cost‐effectiveness analysis: methods for quantitative synthesis in medicine. First Edition. New York: Oxford University Press, 1994:90‐114.
Salach 1994
    1. Salach R, Cash J. Methotrexate: The emerging drug of choice for serious rheumatoid arthritis. Clinical Therapeutics 1994;16(6):912‐22. - PubMed
Schnabel 1994
    1. Schnabel A, Gross Wl. Low‐dose methotrexate in rheumatic diseases: efficacy, side effects and risk factors for side effects. Seminars in Arthritis and Rheumatism 1994;23:310‐27. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Singh 2009
    1. Singh J, Christensen R, Wells G, Suarez Alamor M, Buchbinder R, Lopez Olivo A, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2] - DOI - PMC - PubMed
Singh 2012
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care and Research May 2012;64(5):625‐39. [PUBMED: 22473917] - PMC - PubMed
Stenger 1992
    1. Stenger A, Houtman P, Bruyn G. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?. Annals of the Rheumatic Diseases 1992;51:1019‐20. - PMC - PubMed
Suarez‐Almazor 1998
    1. Suarez‐Almazor ME, Belseck E, Shea B, Tugwell P, Wells GA. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000957] - DOI
Thompson 1984
    1. Thompson R, Watts C, Edelman J, et al. A controlled two‐centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. Journal of Rheumatology 1984;11:760‐3. - PubMed
Tugwell 1987
    1. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Annals of Internal Medicine 1987;107:358‐66. - PubMed
Tugwell 1989
    1. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines. Annals of Internal Medicine 1989;110:581‐3. - PubMed
Wallace 1995
    1. Wallace C, Sherry D. A practical to avoidance of methotrexate toxicity [Editorial]. Journal of Rheumatology 1995;22(6):1009‐12. - PubMed
Weinblatt 1985
    1. Weinblatt M, Coblyn J, Fox D, et al. Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine 1985;312:818‐22. - PubMed
Williams 1985
    1. Williams H, Wilkens R, Samuelson C, et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism 1985;28:721‐30. - PubMed

Publication types

MeSH terms